지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한비만학회 Journal of Obesity & Metabolic Syndrome Journal of Obesity & Metabolic Syndrome Vol.33 No.2
- 발행연도
- 2024.6
- 수록면
- 143 - 154 (12page)
- DOI
- 10.7570/jomes23072
이용수
초록· 키워드
오류제보하기
Background: Muscle–liver crosstalk plays an important role in the development and progression of non-alcoholic fatty liver disease (NAFLD). The measurement of muscle echo-intensity during ultrasonography is a real-time, non-invasive method of assessing muscle quality. In this retrospective study, we investigated the significance of poor muscle quality (namely, a greater mass of non-contractile tissue, including intramuscular fat) as a risk factor for advanced liver fibrosis and considered whether it may represent a useful tool for the diagnosis of advanced liver fibrosis.
Methods: We analyzed data from 307 patients with NAFLD (143 men and 164 women) who visited the University of Tsukuba Hospital between 2017 and 2022. The patients were stratified into the following tertiles of muscle quality according to their muscle echo-intensity on ultrasonography: modest (84.1 arbitrary units [A.U.]), intermediate (97.4 A.U.), and poor (113.6 A.U.). We then investigated the relationships between muscle quality and risk factors for advanced liver fibrosis and calculated appropriate cutoff values.
Results: Patients with poor muscle quality showed a significant, 7.6-fold greater risk of liver fibrosis compared to those with modest muscle quality. Receiver operating characteristic curve analysis showed that muscle quality assessment was as accurate as the fibrosis-4 index and NAFLD fibrosis score in screening for liver fibrosis and superior to the assessment of muscle quantity and strength, respectively. Importantly, a muscle echo-intensity of ≥92.4 A.U. may represent a useful marker of advanced liver fibrosis.
Conclusion: Muscle quality may represent a useful means of identifying advanced liver fibrosis, and its assessment may become a useful screening tool in daily practice.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
Diabetes and Metabolism Journal
2023 .01
-
Association Between Low Muscle Mass and Non-alcoholic Fatty Liver Disease Diagnosed Using Ultrasonography, Magnetic Resonance Imaging Derived Proton Density Fat Fraction, and Comprehensive NAFLD Score in Korea
예방의학회지
2021 .11
-
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
-
Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Diabetes and Metabolism Journal
2022 .07
-
Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
Diabetes and Metabolism Journal
2022 .07
-
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Clinical and Molecular Hepatology
2023 .02
-
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Clinical and Molecular Hepatology
2021 .01
-
비침습적 간섬유화 검사의 적용
대한내과학회지
2023 .04
-
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Clinical and Molecular Hepatology
2023 .02
-
Severe Phenotype of Non-alcoholic Fatty Liver Disease in Pediatric Patients with Subclinical Hypothyroidism: a Retrospective Multicenter Study from Korea
Journal of Korean Medical Science
2021 .01
-
Identification of high-risk subjects in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Clinical and Molecular Hepatology
2021 .01
-
Current role of transient elastography in the management of chronic hepatitis B patients
ULTRASONOGRAPHY
2017 .01
-
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Endocrinology and Metabolism
2020 .01
-
Magnetization-tagged MRI is a simple method for predicting liver fibrosis
Clinical and Molecular Hepatology
2016 .01
-
Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases
Annals of Laboratory Medicine
2021 .01
-
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Clinical and Molecular Hepatology
2023 .02
-
Non-alcoholic Fatty Liver Disease (NAFLD) and Significant Hepatic Fibrosis Defined by Non-invasive Assessment in Patients with Type 2 Diabetes
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Screening strategy for non-alcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Clinical application of liver stiffness measurement for assessing the risk of hepatocellular Carcinoma
Journal of Liver Cancer
2019 .01
최근 본 자료
댓글(0)
0